Compounds > antipyrine

antipyrine and riluzole

antipyrine has been researched along with riluzole in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Kiernan, MC; Noto, Y; Shibuya, K; Vucic, S1
Scott, A1
Rothstein, JD1

Reviews

1 review(s) available for antipyrine and riluzole

ArticleYear
Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Expert review of neurotherapeutics, 2016, Volume: 16, Issue:10

    Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Humans; Motor Neurons; Neuroprotective Agents; Riluzole

2016

Other Studies

4 other study(ies) available for antipyrine and riluzole

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Drug therapy: On the treatment trail for ALS.
    Nature, 2017, 10-18, Volume: 550, Issue:7676

    Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration

2017
Edaravone: A new drug approved for ALS.
    Cell, 2017, Nov-02, Volume: 171, Issue:4

    Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Drug Approval; Edaravone; Excitatory Amino Acid Antagonists; Humans; Riluzole

2017